Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.7%

157 terminated/withdrawn out of 1148 trials

Success Rate

80.5%

-6.0% vs industry average

Late-Stage Pipeline

2%

25 trials in Phase 3/4

Results Transparency

65%

422 of 649 completed trials have results

Key Signals

142 recruiting422 with results121 terminated36 withdrawn

Enrollment Performance

Analytics

Phase 2
454(43.1%)
N/A
304(28.8%)
Phase 1
255(24.2%)
Phase 3
21(2.0%)
Early Phase 1
16(1.5%)
Phase 4
4(0.4%)
1054Total
Phase 2(454)
N/A(304)
Phase 1(255)
Phase 3(21)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1148)

Showing 20 of 1148 trials
NCT01154920Phase 2Active Not Recruiting

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT04479514Phase 2Completed

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Role: lead

NCT01148056Not ApplicableTerminated

Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer

Role: collaborator

NCT04732065Phase 1Recruiting

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Role: collaborator

NCT04290546Phase 1Completed

CIML NK Cell in Head & Neck Cancer

Role: lead

NCT02747888Not ApplicableRecruiting

Hereditary Risk Factors for Thyroid Cancer

Role: lead

NCT05922761Phase 2Recruiting

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Role: lead

NCT07220239Not ApplicableRecruiting

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

Role: collaborator

NCT07513324Phase 2Not Yet Recruiting

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Role: lead

NCT02720679Recruiting

Investigation of the Genetics of Hematologic Diseases

Role: collaborator

NCT01860937Phase 1Active Not Recruiting

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Role: collaborator

NCT07569250Not ApplicableNot Yet Recruiting

Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization

Role: collaborator

NCT06055296Not ApplicableRecruiting

Multisite Implementation of COMPRENDO

Role: collaborator

NCT07624513Phase 3Not Yet Recruiting

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Role: lead

NCT02450708Not ApplicableActive Not Recruiting

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Role: collaborator

NCT05056077Not ApplicableActive Not Recruiting

Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

Role: collaborator

NCT07601100Phase 1Not Yet Recruiting

Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

Role: lead

NCT03319901Phase 1Active Not Recruiting

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Role: lead

NCT03835819Phase 2Active Not Recruiting

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Role: lead

NCT02091245Phase 1Active Not Recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Role: lead